Alibaba DAMO Academy's PANDA AI model, which detects early pancreatic cancer on routine CT scans with 92.9% sensitivity, has received FDA Breakthrough Device Designation after screening more than 70,000 patients in China.
The VA has deployed ambient AI scribes to all primary care teams nationwide, after passing over Microsoft's Nuance in favor of contracts with Abridge and a smaller rival, Knowtex.
Epic said 85% of its healthcare customers are now live on generative AI tools as it rolled out native ambient documentation and previewed a new AI-native interface called Ergo at its 2026 user conference.
Florida's attorney general has sued OpenAI and Sam Altman directly, alleging the company hid safety risks and marketed ChatGPT to children despite knowing about dangerous failures.
Character.AI and Google have quietly settled five lawsuits alleging their chatbots contributed to teen suicides and mental-health harm, even as dozens more cases and state bills pile up nationally.
Tempus AI posted a $5.64 million net profit in Q2 2026 after a $42.84 million loss a year earlier, raised full-year guidance, and moved to acquire Personalis to expand into tumor-monitoring blood tests.
Sanofi and Owkin announced a five-year expansion of their AI partnership on June 5, 2026, licensing Owkin's K Pro platform to build autonomous 'biopharma agents' meant to run multi-step R&D tasks across Sanofi's drug pipeline.
Isomorphic Labs and Johnson & Johnson's Janssen unit announced a cross-modality AI drug-design collaboration on January 20, 2026, extending Isomorphic's platform beyond small molecules into biologics, peptides, and molecular glues aimed at historically undruggable targets.
Isomorphic Labs, the AlphaFold-derived drug-design spinoff of Google DeepMind, raised $2.1 billion on May 13, 2026, the second-largest biotech fundraise ever, betting investors that its AI platform can move from protein prediction to an actual clinical pipeline.
Eli Lilly signed a research and licensing deal worth up to $2.75 billion with Insilico Medicine on March 30, 2026, handing the AI-native biotech's generative drug-design platform a shot at filling Lilly's pipeline with molecules no human chemist screened.